HER2/neu Receptor Antagonist
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About HER2/neu Receptor Antagonist
HER2/neu Receptor Antagonist drugs function by blocking the HER2/neu receptor, a protein that promotes the growth of cancer cells when overexpressed. By inhibiting this receptor, these therapies aim to slow or stop cancer progression. The primary approval for this class is in HER2-overexpressing breast cancer, both in adjuvant and metastatic settings, and also for HER2-overexpressing gastric cancer. The pioneering drug in this class was HERCEPTIN (trastuzumab) by Roche, approved in 1998, which revolutionized the treatment of HER2-positive breast cancer.
The field is actively evolving with the development of biosimilars and next-generation agents. Biosimilars of trastuzumab, such as OGIVRI (trastuzumab-dkst), HERZUMA (trastuzumab-pkrb), ONTRUZANT (trastuzumab-dttb), TRAZIMERA (trastuzumab-qyyp), and KANJINTI (trastuzumab-anns), have entered the market, increasing accessibility and competition. Furthermore, combination therapies, like PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf), which combines pertuzumab and trastuzumab with hyaluronidase for subcutaneous administration, highlight ongoing innovation to improve patient outcomes and convenience. The focus remains on targeting HER2-positive malignancies with increasing precision and efficacy.
10 FDA-approved HER2/neu Receptor Antagonist drugs, including HERCEPTIN, with 81 active Phase 3 trials across 8 indications from 10 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved HER2/neu Receptor Antagonist Drugs
10 totalHER2/neu Receptor Antagonist therapy began with the groundbreaking approval of HERCEPTIN (trastuzumab) by Roche in 1998, establishing a new standard of care for HER2-overexpressing breast cancer. Subsequent advancements have led to the development of related agents and biosimilars. PERJETA (pertuzumab), also from Roche, offers a complementary mechanism by preventing HER2 dimerization, and is approved for both metastatic and early breast cancer. The landscape has been significantly shaped by the introduction of numerous trastuzumab biosimilars, including OGIVRI (trastuzumab-dkst), HERZUMA (trastuzumab-pkrb), ONTRUZANT (trastuzumab-dttb), TRAZIMERA (trastuzumab-qyyp), and KANJINTI (trastuzumab-anns), all approved since 2017, providing more treatment options. Individual HER2/neu Receptor Antagonist drugs differentiate themselves through various characteristics. HERCEPTIN and its biosimilars are typically administered intravenously, while HERCEPTIN HYLECTA and PHESGO offer subcutaneous formulations, improving patient convenience and reducing administration time. PHESGO uniquely combines pertuzumab and trastuzumab, offering dual HER2 blockade in a single injection. MARGENZA (margetuximab-cmkb) is an Fc-engineered antibody designed to enhance natural killer cell-mediated cytotoxicity, potentially offering an advantage in heavily pre-treated patients. These differences in administration, formulation, and mechanism contribute to distinct clinical profiles and positioning. Today, HER2/neu Receptor Antagonist drugs are a cornerstone in the treatment of HER2-positive breast and gastric cancers, often used in first-line, second-line, and subsequent settings. The proliferation of trastuzumab biosimilars has intensified competition and driven down costs, making these therapies more accessible globally. Roche remains a dominant player with its originator products and combination therapies. The standard of care often involves trastuzumab-based regimens, with pertuzumab and margetuximab offering options for specific patient populations or lines of therapy. Class-wide safety profiles are generally well-understood, with cardiotoxicity being a key consideration.
HER2/neu Receptor Antagonist Indications in Trials
Active industry trialsThe active Phase 2 and 3 pipeline for HER2/neu Receptor Antagonist therapies is most heavily concentrated in Breast Cancer, with 11 active trials, followed closely by HER2-positive Breast Cancer with 8 active trials. Gastric Cancer also shows significant activity, with 6 active trials, including 4 specifically for HER2-positive Gastric Cancer. Metastatic Breast Cancer accounts for 5 active trials, and Breast Neoplasms in general have 4 active trials. This indicates a strong ongoing commitment to refining and expanding the use of HER2-targeted agents within these established indications, particularly for breast and gastric malignancies. Beyond the core indications, the pipeline is exploring novel patient subpopulations and combination regimens. While specific new indications are not detailed in the provided data, the focus on HER2-positive subtypes within breast and gastric cancer suggests efforts to optimize treatment for these specific molecular profiles. Combination strategies are likely being investigated to overcome resistance mechanisms and improve efficacy. Trends may include exploring novel antibody-drug conjugates or bispecific antibodies targeting HER2, as well as combining HER2 antagonists with immunotherapies or other targeted agents. The development of subcutaneous formulations like PHESGO also points to a trend towards improved patient convenience. In the next 6-12 months, key readouts are expected from ongoing Phase 2 and 3 trials in breast and gastric cancer, which will further define the role of existing and emerging HER2/neu Receptor Antagonist therapies. Bottleneck disease subsets where the class has historically struggled, such as HER2-low breast cancer or certain refractory gastric cancer settings, may see new approaches tested. Signals suggesting a rich pipeline include the high number of active trials and the continued investment by major sponsors. Conversely, a thinning pipeline might be indicated by a lack of novel targets or a slowdown in new trial initiations, which is not evident from the current data.
Top HER2/neu Receptor Antagonist Sponsors
Industry trials, any indicationHoffmann-La Roche currently leads the active Phase 2/3 trial landscape for HER2/neu Receptor Antagonist therapies with 6 active trials. This dominance stems from their originator status with HERCEPTIN and PERJETA, and their continued investment in developing new formulations like PHESGO and exploring new indications or combinations. Their deep franchise in HER2-targeted therapy provides a strong foundation for ongoing research and development, allowing them to maintain a significant presence in clinical trials across various stages and indications. Key challengers actively competing in the HER2/neu Receptor Antagonist space include Shanghai JMT-Bio Inc. with 6 active trials, AstraZeneca with 5 active trials, and Seagen, a wholly owned subsidiary of Pfizer, along with Genentech, Inc., each with 4 active trials. These sponsors are likely pursuing a mix of biosimilar development, novel antibody engineering, and combination strategies. The competition is particularly fierce in breast and gastric cancer, where multiple players are seeking to improve upon existing standards of care or capture market share with biosimilar versions of established therapies. The strategic landscape for HER2/neu Receptor Antagonist development shows a mix of established innovators and emerging players. While Roche and Genentech represent the originator stronghold, sponsors like Shanghai JMT-Bio Inc. and potentially others from Asia are increasing their activity, suggesting a globalized research effort. Seagen's involvement, as a subsidiary of Pfizer, indicates a strategic focus on antibody-drug conjugates or other advanced modalities. Upcoming catalysts include the release of data from ongoing Phase 3 trials, which could shift the competitive balance by demonstrating superior efficacy or safety. For investors and BD scouts, this dynamic suggests opportunities in both established biosimilar markets and novel therapeutic approaches targeting HER2.
HER2/neu Receptor Antagonist Phase 3 Readout Calendar Pro
12 Phase 3 trials testing approved HER2/neu Receptor Antagonist drugs across 10 indications from 10 sponsors. Earliest readout: Q2 2024.
Coverage: trials whose intervention is an approved HER2/neu Receptor Antagonist drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.